Compare Citius Pharmaceuticals Inc (CTXR) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while MONDELEZ INTERNATIONAL INC Common Stock trades at $58.56 (market cap $75.48B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 5155.7× Citius Pharmaceuticals Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.4% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | MDLZ | |
|---|---|---|
Market Cap | $14.64M | $75.48B |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $70.75 |
52-Week Low | $0.53 | $51.51 |
Enterprise Value | $10.86M | $95.58B |
Dividend Yield | — | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
MDLZ trades at $59.86, up 1.75% today, with a neutral technical signal and bullish moving averages. Revenue grew to $38.54B in 2025, though net income fell to $2.45B. The company maintains strong brand innovation with recent product launches and a new CFO appointment. Analysts show strong buy sentiment with a $68.00 consensus target, implying 13.6% upside.
Outlook remains positive driven by consistent earnings beats and brand strength, but risks include margin pressure from input costs and competitive headwinds. The stock offers a balanced opportunity for growth investors seeking stable consumer staples exposure with dividend income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
